11.13.25 -- We're A Virtual Biotech. CDMOs Should Treat Us As A Priority

Looking for a U.S. based CRO or CDMO? Curia’s 10 U.S. facilities and 30+ year track record can support your small molecule or biologic from curiosity to cure. Whether you’re a small startup with a big idea or an established sponsor seeking additional capacity, Curia can support your discovery, development, or manufacturing needs. Learn more.

Ensuring sterility in pharmaceutical production is one of the most critical safeguards for patient safety. Explore rapid microbiological methods growing impact on sterile drug quality control.

The revised EU GMP Annex 1 prioritizes a CCS. Learn how to holistically manage microbial, particulate, chemical, and cross-contamination risks to ensure product sterility and patient safety.

Review the changing landscape of parenteral delivery, considering the pros and cons of intravenous, subcutaneous, and intramuscular formulations, and how new technologies are reshaping drug delivery.

Follow the journey from master cell bank to large-scale anaerobic fermentation and the unique needs for working with oxygen-sensitive, strictly anaerobic therapeutic microbes in a cGMP setting.

Developing new delivery routes is essential for creating more effective treatments. Nanoforming enables new routes to simplify dosing, enhance patient comfort, and reduce healthcare costs.

The need to optimize cell culture conditions for every cell line in a product-specific manner can lead to extended timelines and substantial cost in cell line development.

Discover how advancements in pharmaceutical freeze-drying are reshaping the process through better product understanding, precise process control, and innovations in equipment efficiency.

Specialized CDMOs are essential for meeting the growing demand and complex quality requirements for sterile injectables, providing benefits like cost savings, flexibility, and more.

Delve into how cloud-based systems and unified data platforms are transforming biomanufacturing by enhancing efficiency, ensuring quality, and accelerating the delivery of complex therapies to market.

An unaddressed compliance issue related to contamination control can pose a significant risk to a life sciences organization. This study details a company's journey toward sustainable compliance.

To accelerate COVID-19 vaccine production, biologics contract manufacturer Catalent sought high-speed labeling machines that could be rapidly deployed.

A solution and partner that can help biopharmaceutical companies manage costs will be essential to achieve commercial success in a market that will only become more competitive.

This presentation highlights the strategies executed to meet the needs of a program without sacrificing the thorough scientific evaluation of the process required for a successful validation campaign.

Challenges in transferring your biological product from development to manufacturing? Consider the following strategies for tech transfer, regulatory compliance, quality, and consistency.

Gain access to industry-leading scientific capabilities, integrated platforms, and specialized expertise that help streamline antibody-drug conjugate discovery and development.

With proven expertise in process development, optimization, and CGMP manufacturing, Avid offers end-to-end CDMO solutions backed by flexible capacity designed to scale with program needs.

With our high-productivity and single-use technology, we provide you with a continuous manufacturing approach with easy-to-modulate capacity and efficient end-to-end sustainable processes.

Tailored support is available for diverse molecules, including small and large molecules, nucleic acid therapies, and novel delivery systems. Services span drug substance to regulatory affairs.

Accelerate sterile injectable development with expert support, advanced facilities, and tailored solutions for complex APIs — from formulation through commercialization across small molecules and biologics.